These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1046 related articles for article (PubMed ID: 19553142)
1. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142 [TBL] [Abstract][Full Text] [Related]
2. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Samy W; Hassanian MA Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478 [TBL] [Abstract][Full Text] [Related]
3. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
4. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040 [TBL] [Abstract][Full Text] [Related]
5. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612 [TBL] [Abstract][Full Text] [Related]
6. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224 [TBL] [Abstract][Full Text] [Related]
7. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278 [TBL] [Abstract][Full Text] [Related]
8. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes. Ferrer-García JC; Sanchez-Ballester E; Albalat-Galera R; Berzosa-Sanchez M; Herrera-Ballester A J Cardiovasc Pharmacol Ther; 2008 Sep; 13(3):183-8. PubMed ID: 18635754 [TBL] [Abstract][Full Text] [Related]
10. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877 [TBL] [Abstract][Full Text] [Related]
11. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus. Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735 [TBL] [Abstract][Full Text] [Related]
12. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. Uemura Y; Watarai M; Ishii H; Koyasu M; Takemoto K; Yoshikawa D; Shibata R; Matsubara T; Murohara T J Cardiol; 2012 Jan; 59(1):50-6. PubMed ID: 22100058 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M; Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022 [TBL] [Abstract][Full Text] [Related]
15. Effect of atorvastatin on type 2 diabetic dyslipidemia. Save V; Patil N; Moulik N; Rajadhyaksha G J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):262-70. PubMed ID: 17220473 [TBL] [Abstract][Full Text] [Related]
16. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy. Li C; Gu Q Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863 [TBL] [Abstract][Full Text] [Related]
17. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. Rock W; Rosenblat M; Miller-Lotan R; Levy AP; Elias M; Aviram M J Agric Food Chem; 2008 Sep; 56(18):8704-13. PubMed ID: 18759451 [TBL] [Abstract][Full Text] [Related]
18. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Geiss HC; Otto C; Schwandt P; Parhofer KG Metabolism; 2001 Aug; 50(8):983-8. PubMed ID: 11474489 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077 [TBL] [Abstract][Full Text] [Related]
20. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia. Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]